Medium-chain acyl-CoA dehydrogenase deficiency (MCADD)


MCAD deficiency is a metabolic disorder. MCAD is an enzyme found in the mitochondria that is responsible for the metabolism of medium chain fatty acids. When this enzyme is missing, the body is unable to convert these fatty acids to energy during times of decreased food intake. Individuals who are MCAD deficient are not able to fast for extended periods of time because of the inability to convert the body's fat to energy when the food store has run out. When individuals with MCAD do fast, they experience a range of serious life threatening symptoms or even death.


There are no symptoms of MCAD at birth. Symptoms of MCAD deficiency generally begin to occur between the second month and second year of life. Symptoms occur when in a fasting state, often due to illness, and include hypoglycemia, vomiting, lethargy, liver dysfunction, seizures, and coma. Affected individuals are usually symptom free between episodes. If left untreated, brain damage, cardiac arrest, serious illness, and death can occur.


MCAD deficiency is inherited in an autosomal recessive fashion. A single gene change, K304E, accounts for 90% of MCAD deficiency cases. This gene is located on chromosome 1. Eighty-one percent of individuals with MCAD deficiency are homozygous for this mutation. Individuals who are heterozygous (carriers) have no symptoms. When two carriers (heterozygotes) have children, the risk is 1 in 4 or 25% their children will have MCAD deficiency: 25% their children will have no changed MCAD genes; and 50% their children will be carriers like themselves and have no MCAD deficiency symptoms.


In order to distinguish MCAD from other fatty acid metabolic disorders, multiple tests must be performed which include the clinical status of the patient at the time of the test. Initial laboratory testing for MCAD should include the analyses of plasma acylcarnitines, plasma-free fatty acids, urine organic acids, and urine acylglycines. Tandem mass spectrometry is the most recently developed test for population-based screening of MCAD. This test is usually followed by confirmatory DNA (genetic) studies. Testing should be initiated in individuals with the following indications: * Prenatal diagnosis for carrier couples * Carrier screening in families of affected individuals * Intermittent hypoglycemia * Carnitine deficiency * Urinary excretion of medium chain fatty acids and decreased ketones * Vomiting, lethargy, and/or coma following fasting Risk factors include finding fatty infiltration of the liver, family history of sudden death, Reye's Syndrome, myopathy, and decreased caloric intake before death. All siblings of individuals with MCAD should be tested even if they are without symptoms.


* Prognosis is difficult, because of the broad clinical spectrum. * The majority of children do well, if appropriately treated.


Treatment for MCAD deficiency is simple and allows for a good prognosis. Treatment consists of avoiding fasting for more than 2-6 hours in an infant. After infancy, overnight fasts of longer than 12 hours should be avoided. These values may vary from person to person. A high carbohydrate diet with restriction of fats and supplemental carnitine is recommended, especially during illness. The treatment regimen must be followed throughout the lifetime of the affected individual. Fasting should especially be avoided during times of illness. If an individual is unable to keep down fluids, has diarrhea or a fever, he or she should be evaluated promptly and given intravenous glucose immediately following blood chemistry sampling. Some doctors may prescribe a drug called L-Carnitine to children. This drug helps the child's blood sugar from getting low when they have infections or don't eat. L-Carnitine is a substance made by the body that carries wastes out of body cells and into the urine. Individuals with MCAD make more toxic wastes than normal individuals so they need more L-Carnitine to carry out this process.